Sex Differences in Early Brain Development; Brain Development in Turner Syndrome

Turner Syndrome Clinical Trial

Official title:

Sex Differences in Early Brain Development; Brain Development in Turner Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00877942
• Other study ID #: K01MH083045-01
• Secondary ID: 1K01MH083045-01
• Status: Completed
• Phase: N/A
• First received: April 6, 2009
• Last updated: May 1, 2014
• Start date: October 2006
• Est. completion date: May 2014

Study information

• Verified date: May 2014
• Source: University of North Carolina, Chapel Hill
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review BoardUnited States: Federal Government
• Study type: Observational

Clinical Trial Summary

Relative risk for many psychiatric disorders differs dramatically in males and females. Early-onset disorders, such as autism, occur more often in males; other conditions, such as schizophrenia, occur at similar rates in males and females, but the sexes differ in expression. It has been hypothesized that the prevalence and expression of these disorders is related to sex differences in brain development. X-chromosome effects and early exposure to gonadal hormones are strong candidates for a causal role. The aims of the research are (1) to characterize sex differences in brain development from birth to age 2; (2) to test whether brain development is altered in infants with Turner syndrome, a well-defined genetic disorder resulting from the partial or complete loss of one of the sex chromosomes. To address aim 1, high resolution MRI, including diffusion tensor imaging (DTI), will be used to characterize sex differences in brain development from birth to age 2 in a longitudinal cohort of 250 children. To address aim 2, high resolution MRI, including DTI, will be used to compare brain development in 70 infants with Turner syndrome (X monosomy) to matched controls from aim 1. The investigators hypothesize that sex differences in gray and white matter development and in white matter maturation as assessed by DTI will be present during the first 2 years of life and that children with TS will exhibit abnormal gray and white matter development in the neonatal period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 295
• Est. completion date: May 2014
• Est. primary completion date: May 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: N/A to 2 Years

Eligibility

Inclusion Criteria:

• For controls a child must have a normal ultrasound at the 18 week prenatal visit and the absence of major medical or psychiatric conditions in the mother.

• Children with Turner Syndrome must have diagnosis confirmed by genetic testing.

Exclusion Criteria:

• For controls - major medical or psychiatric conditions in the mother and major medical problems or congenital conditions in the child.

• For Turner children - The study is open to all TS karyotypes except those with Y chromosome material.

• For both groups children with conditions that preclude participating in an MRI scan ( i.e. metal in the body)

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Gonadal Dysgenesis
• Primary Ovarian Insufficiency
• Syndrome
• Turner Syndrome

Locations

Country	Name	City	State
United States	University of North Carolina at Chapel Hill	Chapel Hill	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
University of North Carolina, Chapel Hill	National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Brain volumes on MRI		2-4 weeks post birth	No
Secondary	Brain volumes and DTI parameters		2-4 weeks post birth, 1 yr, 2 yr	No